布拉氏酵母菌辅助治疗儿童幽门螺杆菌感染研究进展
Research Progress of Saccharomyces boulardii as an Adjuvant Therapy for Helicobacter pylori Infection in Children
DOI: 10.12677/acm.2026.1693183, PDF,   
作者: 王梦缘：承德医学院研究生学院，河北 承德；夏 红*：邢台市人民医院儿一科，河北 邢台
关键词: 幽门螺杆菌；布拉氏酵母菌；儿童；治疗；Helicobacter pylori； Saccharomyces boulardii； Children； Treatment
摘要: 幽门螺杆菌(Helicobacter pylori, Hp)是一种定植于胃黏膜的微需氧、螺旋状革兰氏阴性菌，与多种胃内外疾病密切相关，且在儿童群体发病率高，对儿童生长发育造成了严重危害。由于抗生素耐药率升高、不良反应增加、依从性差等因素，传统方案抑酸剂联合抗生素的根除效果已不能满足临床需求。近年来，越来越多的研究表明将益生菌作为儿童Hp感染根除治疗的辅助手段，可以显著降低治疗过程中不良反应的发生率，提高患儿依从性。布拉氏酵母菌是一种耐酸、耐抗生素的非致病性真菌制剂，与常规根除方案联合应用的安全性高。因此，本文通过总结布拉氏酵母菌在儿童群体的应用效果，以期为儿童Hp的根除治疗提供参考。
Abstract: Helicobacter pylori (Hp) is a microaerophilic, spiral Gram-negative bacterium colonized in the gastric mucosa. It is closely related to a variety of gastric and extra-gastric diseases, and has a high incidence in children, causing serious harm to children’s growth and development. Due to factors such as increased antibiotic resistance, increased adverse reactions, and poor compliance, the eradication effect of traditional regimen proton pomp inhibitors combined with antibiotics has been unable to meet clinical needs. In recent years, more and more studies have shown that probiotics as an adjunct to the eradication of Hp infection in children can reduce the incidence of adverse reactions during treatment, improve patients’ compliance. Saccharomyces boulardii is a kind of acid-resistant and antibiotic-resistant non-pathogenic fungal preparation, which has high safety when combined with conventional eradication regimen. Therefore, this article reviews the application of Saccharomyces boulardii in children, in order to provide reference for the eradication treatment of Hp in children.
文章引用：王梦缘, 夏红. 布拉氏酵母菌辅助治疗儿童幽门螺杆菌感染研究进展[J]. 临床医学进展, 2026, 16(9): 1451-1457. https://doi.org/10.12677/acm.2026.1693183

参考文献

[1] 张泽惠, 张慧芳, 肖瑶, 等. 幽门螺杆菌形态变化超微结构分析[J]. 中国病原生物学杂志, 2023, 18(9): 1034-1038.
[2] Malfertheiner, P., Camargo, M.C., El-Omar, E., Liou, J., Peek, R., Schulz, C., et al. (2023) Helicobacter pylori Infection. Nature Reviews Disease Primers, 9, Article No. 19.
https://doi.org/10.1038/s41572-023-00431-8
[3] 中华医学会儿科学分会消化学组, 国家儿童医学中心消化专科联盟, 中华儿科杂志编辑委员会. 中国儿童幽门螺杆菌感染诊治专家共识(2022) [J]. 中华儿科杂志, 2023, 61(7): 580-587.
[4] Homan, M., Jones, N.L., Bontems, P., Carroll, M.W., Czinn, S.J., Gold, B.D., et al. (2024) Updated Joint ESPGHAN/NASPGHAN Guidelines for Management of Helicobacter pylori Infection in Children and Adolescents (2023). Journal of Pediatric Gastroenterology and Nutrition, 79, 758-785.
https://doi.org/10.1002/jpn3.12314
[5] Malfertheiner, P., Megraud, F., Rokkas, T., Gisbert, J.P., Liou, J., Schulz, C., et al. (2022) Management of Helicobacter pylori Infection: The Maastricht VI/Florence Consensus Report. Gut, 71, 1724-1762.
https://doi.org/10.1136/gutjnl-2022-327745
[6] Yuan, C., Adeloye, D., Luk, T.T., Huang, L., He, Y., Xu, Y., et al. (2022) The Global Prevalence of and Factors Associated with Helicobacter pylori Infection in Children: A Systematic Review and Meta-Analysis. The Lancet Child & Adolescent Health, 6, 185-194.
https://doi.org/10.1016/s2352-4642(21)00400-4
[7] 黎文鸿, 李紫薇, 汪娜, 等. 中国儿童幽门螺杆菌感染现状及其影响因素的Meta分析[J]. 中国全科医学, 2022, 25(28): 3569-3578.
[8] Xu, L., Li, X., Ur-Rahman, I., Zhang, C., Qi, Y., Hu, R., et al. (2024) Global H. pylori Recurrence, Recrudescence, and Re-Infection Status after Successful Eradication in Pediatric Patients: A Systematic Review and Meta-Analysis. Journal of Gastroenterology, 59, 668-681.
https://doi.org/10.1007/s00535-024-02114-x
[9] 李红, 杨天阔, 申亚琳, 等. 幽门螺杆菌药敏检测方法研究进展[J]. 中华医学杂志, 2020, 100(30): 2393-2396.
[10] Chey, W.D., Howden, C.W., Moss, S.F., Morgan, D.R., Greer, K.B., Grover, S., et al. (2024) ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. American Journal of Gastroenterology, 119, 1730-1753.
https://doi.org/10.14309/ajg.0000000000002968
[11] 王航宇, 刘琳琳, 向淼, 等. 幽门螺杆菌致病机制的多角度分析: 毒力因子及外泌体[J]. 中国组织化学与细胞化学杂志, 2024, 33(2): 170-175.
[12] Doohan, D., Rezkitha, Y.A.A., Waskito, L.A., Yamaoka, Y. and Miftahussurur, M. (2021) Helicobacter pylori BabA-SabA Key Roles in the Adherence Phase: The Synergic Mechanism for Successful Colonization and Disease Development. Toxins, 13, Article 485.
https://doi.org/10.3390/toxins13070485
[13] Akhlaq, M., Rizwani, G.H., Sultana, S., et al. (2025) Urease Enzyme: Structure, Function, and Its Role in Helicobacter pylori Patho-Genesis and Treatment Strategies. Annual Methodological Archive Research Review, 3, 1088-1111.
[14] 苏娜贇, 王廷义, 左钱飞, 等. 幽门螺杆菌毒力因子CagA通过靶向SHARPIN促进炎症反应的机制研究[J]. 免疫学杂志, 2023, 39(12): 1021-1027.
[15] Cheok, Y.Y., Lee, C.Y.Q., Cheong, H.C., Vadivelu, J., Looi, C.Y., Abdullah, S., et al. (2021) An Overview of Helicobacter pylori Survival Tactics in the Hostile Human Stomach Environment. Microorganisms, 9, Article 2502.
https://doi.org/10.3390/microorganisms9122502
[16] Hou, C., Yin, F., Wang, S., Zhao, A., Li, Y. and Liu, Y. (2022) Helicobacter pylori Biofilm-Related Drug Resistance and New Developments in Its Anti-Biofilm Agents. Infection and Drug Resistance, 15, 1561-1571.
https://doi.org/10.2147/idr.s357473
[17] 赵明明, 董莉真, 贾子超, 等. 幽门螺杆菌定植因子的作用机制[J]. 国际检验医学杂志, 2025, 46(11): 1370-1374, 1408.
[18] Kaźmierczak-Siedlecka, K., Ruszkowski, J., Fic, M., Folwarski, M. and Makarewicz, W. (2020) Saccharomyces boulardii CNCM I-745: A Non-Bacterial Microorganism Used as Probiotic Agent in Supporting Treatment of Selected Diseases. Current Microbiology, 77, 1987-1996.
https://doi.org/10.1007/s00284-020-02053-9
[19] 向金波, 罗军, 胡小燕, 等. 布拉氏酵母菌防治儿童抗生素相关性腹泻的研究进展[J]. 中国药房, 2021, 32(8): 1020-1024.
[20] 胡宇婷, 李晓丽. 布拉迪酵母菌在幽门螺杆菌感染治疗中的应用进展[J]. 中国微生态学杂志, 2025, 37(8): 972-976.
[21] Sakarya, S. and Gunay, N. (2014) Saccharomyces boulardii Expresses Neuraminidase Activity Selective for α2,3‐Linked Sialic Acid That Decreases Helicobacter pylori Adhesion to Host Cells. APMIS, 122, 941-950.
https://doi.org/10.1111/apm.12237
[22] 梅昭均, 李丹丹, 罗再春, 等. 布拉酵母菌补充三联疗法根除儿童幽门螺杆菌的疗效: 随机对照试验的Meta分析[J]. 中国微生态学杂志, 2020, 32(2): 161-165.
[23] Fujimura, S., Watanabe, A., Kimura, K. and Kaji, M. (2012) Probiotic Mechanism of Lactobacillus gasseri OLL2716 Strain against Helicobacter pylori. Journal of Clinical Microbiology, 50, 1134-1136.
https://doi.org/10.1128/jcm.06262-11
[24] Ande, S.N., Mudholkar, K.R., Bakal, R.L., et al. (2022) Is Saccharomyces boulardii an Ideal Probiotic in Management of Gastrointestinal Diseases? A Review. Innovations in Pharmaceuticals and Pharmacotherapy, 10, 41-45.
[25] 黄文莎, 张圣杰, 季梦遥, 等. 布拉氏酵母菌辅助治疗幽门螺杆菌感染的研究进展[J]. 胃肠病学和肝病学杂志, 2025, 34(7): 1061-1066.
[26] 王威, 李金平, 赵宗禹. 布拉氏酵母菌在治疗幽门螺杆菌感染中的应用现状[J]. 中国感染控制杂志, 2018, 17(7): 638-641.
[27] Cárdenas, P.A., Garcés, D., Prado-Vivar, B., Flores, N., Fornasini, M., Cohen, H., et al. (2020) Effect of Saccharomyces boulardii CNCM I-745 as Complementary Treatment of Helicobacter pylori Infection on Gut Microbiome. European Journal of Clinical Microbiology & Infectious Diseases, 39, 1365-1372.
https://doi.org/10.1007/s10096-020-03854-3
[28] Gopalan, S., Ganapathy, S., Mitra, M., Kumar Joshi, D., Veligandla, K.C., et al. (2023) Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review. Cureus, 15, e46314.
https://doi.org/10.7759/cureus.46314
[29] 周颖, 王玉环, 芦军萍, 等. 上海市单中心儿童幽门螺杆菌不同治疗方案根除率及其耐药率的横断面调查[J]. 中国循证儿科杂志, 2019, 14(2): 81-86.
[30] Liu, L.H., Han, B., Tao, J., Zhang, K., Wang, X. and Wang, W. (2023) The Effect of Saccharomyces boulardii Supplementation on Helicobacter pylori Eradication in Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. BMC Infectious Diseases, 23, Article No. 878.
https://doi.org/10.1186/s12879-023-08896-4
[31] 赵红梅, 欧阳红娟, 段柏平, 等. 三联疗法联合布拉氏酵母菌治疗儿童幽门螺杆菌感染的临床研究[J]. 中国当代儿科杂志, 2014, 16(3): 230-233.
[32] 徐洁. 布拉酵母菌辅助治疗儿童幽门螺杆菌感染的应用效果[J]. 中国社区医师, 2016, 32(21): 88-89.
[33] 周承, 殷海斌, 周罗根. 益生菌联合序贯疗法治疗儿童幽门螺杆菌感染的疗效分析[J]. 实用临床医药杂志, 2018, 22(24): 62-65.
[34] 罗威耀, 黄为民, 万瑞平, 等. 序贯疗法联合布拉氏酵母菌根除儿童幽门螺杆菌感染的疗效评价[J]. 现代生物医学进展, 2023, 23(17): 3237-3241.
[35] 张敬, 王跃生, 李小芹, 等. 不同时期添加布拉氏酵母菌散联合三联疗法治疗儿童幽门螺杆菌感染的效果[J]. 河南医学研究, 2021, 30(20): 3670-3673.
[36] 房路路, 沈栋林, 常煜胤, 等. 不同疗程布拉酵母菌散根除儿童幽门螺杆菌的疗效分析[J]. 医学研究杂志, 2023, 52(11): 175-179.

为你推荐